Corbus Pharmaceuticals Holdings, Inc.
$10.62
▲
1.9%
2026-04-21 06:12:01
www.corbuspharma.com
NCM: CRBP
Explore Corbus Pharmaceuticals Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$188.36 M
Current Price
$10.62
52W High / Low
$20.56 / $5.75
Stock P/E
—
Book Value
$8.38
Dividend Yield
—
ROCE
-57.84%
ROE
-54.18%
Face Value
—
EPS
$-5.9
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
36
Beta
2.79
Debt / Equity
1.11
Current Ratio
8.07
Quick Ratio
8.07
Forward P/E
-2
Price / Sales
—
Enterprise Value
$12.18 M
EV / EBITDA
-0.14
EV / Revenue
—
Rating
Strong Buy
Target Price
$40.56
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Traws Pharma, Inc. | $1.39 | — | $14.12 M | — | -185.49% | -10.6% | $3.27 / $0.97 | $0.64 |
| 2. | Intellia Therapeutics, Inc. | $15.21 | — | $1.8 B | — | -59.74% | -53.48% | $28.25 / $6.8 | $5.77 |
| 3. | Capricor Therapeutics, Inc. | $34.21 | — | $2.04 B | — | -33.78% | -46.56% | $40.37 / $4.3 | $5.33 |
| 4. | Eledon Pharmaceuticals, Inc. | $4.14 | — | $314.03 M | — | -55.26% | -35.79% | $4.6 / $1.35 | $1.81 |
| 5. | Arrowhead Pharmaceuticals, Inc. | $71.64 | 46.54 | $10.05 B | — | 8.27% | 75.5% | $76.76 / $10.92 | $4.14 |
| 6. | Jasper Therapeutics, Inc. | $1.06 | — | $28.56 M | — | -371.51% | -2.3% | $7.19 / $0.62 | $0.15 |
| 7. | Mirum Pharmaceuticals, Inc. | $95.71 | — | $5.78 B | — | -3.47% | -8.65% | $109.28 / $38.22 | $6.06 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -21.97 M | -24.42 M | -19.15 M | -19.77 M | -12.61 M | — |
| Net Profit | -20.55 M | -23.34 M | -17.66 M | -16.98 M | -9.53 M | — |
| EPS in Rs | -1.16 | -1.32 | -1 | -0.96 | -0.54 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -85.31 M | -48.72 M | -45.08 M | -34.84 M |
| Net Profit | -78.54 M | -40.21 M | -44.6 M | -42.35 M |
| EPS in Rs | -4.43 | -2.27 | -2.51 | -2.39 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 168.19 M | 155.88 M | 28.27 M | 66.31 M |
| Total Liabilities | 20.69 M | 13.45 M | 35.18 M | 33.32 M |
| Equity | 147.5 M | 142.43 M | -6.91 M | 32.99 M |
| Current Assets | 166.95 M | 152.98 M | 23.55 M | 60.18 M |
| Current Liabilities | 20.69 M | 11.82 M | 31.89 M | 12.64 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -64.49 M | -41.79 M | -36.1 M | -37.54 M |
| Investing CF | -1.64 M | -121.31 M | 35.64 M | 30.07 M |
| Financing CF | 77.43 M | 166.58 M | -2.82 M | -0.53 M |
| Free CF | -64.5 M | -41.79 M | -36.1 M | -37.56 M |
| Capex | -0.01 M | — | — | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 9.85% | -5.33% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-02-14 | 1:0.0333333 |